Health authorities in Belgium say a lab-made concentrated vitamin E derived from the skin of humans has shown efficacy in treating dermatitis, a serious skin condition that causes inflammation and blistering.
The vitamin, called derma-pigment pectin, is derived from a plant that is a member of the plant family Carya.
The product, which was approved for human use last month by the European Union, has been in the pipeline since 2015, when it was tested in a small clinical trial of patients with dermatitis.
The company says it hopes to begin selling the product commercially in 2017.
The trial was conducted at the Universite Catholique de Louvain in Belgium and involved the use of topical ointments that blocked some of the skin’s natural barrier function.
“The trial demonstrated that the skin barrier can be effectively blocked with derma pigment pectins,” said the company in a statement.
“This led us to conclude that derma pigments are a potential alternative for the treatment of dermatitis.”
The company also said the study demonstrated the effectiveness of the derma skin pigment pampers on the inflammatory process in the skin.
Derma pigmentation pampeters are available as a gel or oil-based solution and are sold under a variety of brand names.
The products were approved for use in Belgium as a topical solution and for use by humans, but the company has not yet been able to produce them commercially in the United States, according to the FDA.
The study, which involved 683 patients, was conducted in Belgium’s Maudsley hospital in the city of Antwerp and involved an open-label trial.
It found that the treatment significantly improved symptoms and pain in patients with severe dermatitis compared with placebo.
“It is important to note that the results do not indicate that dermal derma pampering is the most effective treatment,” said Dr. Paul van Dijk, the study’s lead author.
“Nevertheless, we can say that this treatment is clinically effective in the treatment and control of dermatitic symptoms.”
Dermatitis is a condition in which the immune system attacks the skin and can lead to inflammation and scarring.
Dermatopathies can also be caused by a number of other conditions, including a weakened immune system.
A small group of patients treated with dermagen pampercerin showed improvement in their skin’s barrier function, the company said.
Dermal pigments can also help to improve the function of the immune systems of patients who have been diagnosed with psoriasis, the FDA said.
The U.S. Food and Drug Administration approved derma treatments as an alternative to drugs that work by attacking the skin, but there have been reports of side effects that have made derma therapies less safe than their drugs.
The FDA also has not approved a drug that treats psoroiditis, which is a chronic, inflammatory skin disorder.
However, the agency has approved the treatment as a temporary measure that will be withdrawn once patients show improvement.
A spokeswoman for the FDA’s division that approves new drugs said the agency is reviewing the results of the study and will issue a final ruling in the coming weeks.
The new drug is also under investigation by the Centers for Disease Control and Prevention and the U.K.’s National Health Service, the Health Protection Agency, the U